New York Community Bank Gets A Lifeline… And Heavy Costs For Weight-Loss Drugs 3/6/24

6 Mar 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Summary: CNBC's "Fast Money"

Episode Title

New York Community Bank Gets A Lifeline… And Heavy Costs For Weight-Loss Drugs (3/6/24)

---

Episode Overview In this episode of "Fast Money," hosted by Melissa Lee, the discussion centers around the recent $1 billion equity raise by the New York Community Bank Corp (NYCB) led by former Treasury Secretary Steve Mnuchin. The episode also tackles the rising costs of weight-loss drugs and their implications for consumers and government spending.

Key Topics Discussed

  1. Lifeline for New York Community Bank Corp
  2. Investment Details:
  3. NYCB secured a $1 billion investment led by Mnuchin’s firm, Liberty Strategic Capital.
  4. Investment included common and convertible preferred stock at $2 per share, with 60% warrant coverage.
  5. Investor Confidence:
  6. The investment helped stabilize NYCB after shares plummeted by 42% earlier in the day.
  7. Positive investor sentiment returned, as the stock closed up 7.5%.
  8. Management Concerns:
  9. The appointment of a new management team and board was seen as a confidence booster for investors.
  10. Ongoing concerns about the bank's internal controls and loan reviews were highlighted.
  1. Comparisons to Past Banking Crises
  2. Historical Context:
  3. Discussion of Mnuchin's previous bailout of IndyMac during the financial crisis.
  4. Concerns of a potential repeat of the failures seen with Silicon Valley Bank (SVB).
  5. Regulatory Issues:
  6. Insights into how crossing the $100 billion asset threshold increased regulatory scrutiny for NYCB.
  7. Discussion on the implications of commercial real estate exposure for regional banks.
  1. Weight-Loss Drug Costs
  2. Rising Costs:
  3. Exploration of how increasing prices for effective obesity drugs like Ozempic and Wegovy may limit accessibility for patients who need them.
  4. Government Action:
  5. Former NEC Director Brian Deese’s op-ed urged for government intervention to negotiate drug prices through Medicare.
  6. Dr. Scott Gottlieb provided insights, countering some of the estimates regarding costs to Medicare.
  7. Discussion on the potential impact of these drugs on overall healthcare costs, especially concerning comorbidities like obesity-related conditions.
  1. Market Reactions and Future Outlook
  2. Response to Fed Testimony:
  3. Commentary on Fed Chair Jerome Powell’s stance on interest rates and economic resilience.
  4. Insights into market behavior and investor sentiment following the Fed’s announcements.
  5. Stock Market Dynamics:
  6. Discussion on Lyft's stock performance and potential for recovery.
  7. Foot Locker's significant drop in stock price after disappointing earnings and future guidance.

Key Takeaways

  • The financial stability of NYCB is buoyed by strategic investments, but ongoing regulatory scrutiny and internal control weaknesses remain concerns.
  • The significant increase in costs for weight-loss drugs could restrict access for many, prompting calls for governmental price negotiations.
  • General market sentiments are mixed, with specific stocks like Lyft showing potential upside against a backdrop of cautious optimism regarding economic policies from the Fed.

Conclusion The episode of "Fast Money" provides a thorough examination of critical financial developments impacting both the banking sector and healthcare drug pricing. The discussions reflect on investor confidence dynamics, historical parallels to previous crises, and the broader implications for the economy and public health.

For more detailed information and analysis, visit [CNBC's Fast Money](http://fastmoney.cnbc.com).

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Live from the Nasdaq market site in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. Back from the brink, New York Community Bank Corp getting a billion-dollar lifeline from the former Treasury Secretary Steven Mnuchin one year after SVB failed. How did another major bank almost blow up? We'll have the very latest. Plus, the battle over bulge. Former FDA Commissioner Scott Gottlieb set to weigh in on the call for the government to step in and get prices lowered for these wildly popular and effective obesity drugs. And later, Tim is pumping up the L in his blicep trade.

0:32Blicep. playing that, topping the tape on a big Chinese tech name. And two left beats, the reasons why Foot Locker dropped almost 30 percent today. I'm Melissa Lee. Come to you live from Studio B at the Nasdaq on the desk tonight. Tim Seymour, Karen Feinemann, Steve Rosso, and Savita Subramanian, head of U.S. equity strategy for Bank of America, B of A. Markets, meantime, managing gains across the board as investors look to recoup some of yesterday's losses, though all three indices did close well off the day's highs. Fed chair Jerome Powell reiterating that the central bank is not ready to cut rates just yet.

1:03We'll get more on that in just a few minutes. But we start off with a last-minute lifeline for New York Community Bancorp. Shares were down as much as 42 percent today before the regional lender announced it had secured a billion-dollar investment led by the firm of former Treasury Secretary Steven Mnuchin. After several trading halts, shares managed to close the day higher, 7.5 percent. That is less than 25 cents higher, I should say. For the latest details. Let's get straight to Leslie Picker, who joins us here on set. What a rollercoaster day today. Oh, my gosh. It was a fascinating turn of events for this company, New York Community Bancorp, inking a deal for$1 billion from a group of investors led by former Treasury Secretary Steven Mnuchin's firm Liberty Strategic Capital.

1:45Those investors buying common and convertible preferred stock,$2 per share. Investors will also get a 60 % warrant coverage to buy more stock with an exercise price of$250. A bit of background on how this all came together, according to people familiar with the matter. Secretary Mnuchin had been involved here diligencing NYCB for a while now. I'm told Jeffries approached a select group of other investors with the prospect of a capital raise on Sunday. They were told that a lead investor, Mnuchin's firm, had put up$450 million. Ultimately, investors including Hudson Bay Capital, Reverence Capital Partners, and Citadel had had decided to invest alongside him for a total infusion of that$1 billion.

2:27I'm told that putting former comptroller of the currency, Joseph Otting, in the CEO role and revamping the board was a boost of confidence for investors to join in here. The price per share of$2 was finalized intraday after the stock plummeted. It's a premium to the lows of today, but below any level that NYCB has closed since the late 90s. Still, the stock is reacting positively because investors believe that the equity stabilizes the bank, whereas the stock moves prior to this announcement were more reflective of a likelihood of failure. Melissa? I think Mnuchin stepping in is a really interesting twist given his track record bailing out IndyMac during the great financial crisis.

3:09At the time, that was the third biggest failure amongst banks in U.S. history. And I guess there's sort of a dance being done in terms of when to step in, how far do you let New York Community Bancorp fall? and whether or not you just wait until it does. If you're a public market investor, there's just been such a slew of headlines surrounding this company. It was just last week where they revealed their material weaknesses and internal controls related to loan review. That review is ongoing. So there's been this sense among the investor community of what could pop up next. And that's been the main concern and why they've really struggled to find stability here.

3:43They did have a couple weeks of stability. You saw some insider buys. It seemed like things were kind of under control. But now there's just so much uncertainty. So what today's news showed, and I think that's why you saw the stock close up a decent amount today, is that, you know, you have this new management team in place, a management team that is very familiar with the regulatory environment, which is extremely important as this company is now over$100 billion in assets. So regulated much more strictly than they were back in 2022. You've been pouring over this. Yeah, I find the whole thing.

4:18It is fascinating. I think, you know, Leslie's talking about the fear of failure. I think we were hours from failure, less than one day from failure. I don't think that the stock could have opened again tomorrow without there having been something cataclysmic. So interesting timing for them to price a an equity offering and a convert and the warrants. But I imagine that NYCB had absolutely zero negotiating leverage. None. So this is very good. There's life for the bank. It was trading as if it was an option that was about to expire. So now there's life to the option. I don't know that it addresses some of the other issues.

4:58So we know that they had this goodwill of$2.4 billion. This is going back to last week. All of a sudden they're saying, all right, you know what? That goodwill should be worth zero. Now, that doesn't actually affect the tangible book value, But it does raise questions of why have you never looked to write down that goodwill before now? I don't know. Maybe it had to do with them talking to Mnuchin and others. It's fascinating. It's good that they're getting new management, particularly after that crazy ride last week where we saw the head of the board step down and say in protest. I don't think he should be our guy, which you brought up the point.

5:34Maybe it was because some of the things they bought under Flagstar. I don't know. The goodwill didn't change between before Flagstar and after. It didn't change much between when they did the signature deal. So I don't know what the disclosure hasn't been fantastic. So, yeah. And I also would imagine they were calling Jamie Dimon and he was like, no, I am not taking this call. No, you point out the disclosure aspect. And there's this sense of mistrust among the investor community because, remember, they lost their head of risk and their head of audit back in December. it was never disclosed. They just kind of disappeared from the website.

6:10And then suddenly media reports showed that those two individuals had departed. It took a few weeks to fill those roles. It was reminiscent of SVB. Yes, exactly. And that's why I think when headlines hit the wires earlier today saying that they were looking for equity capital, a lot of people had this deja vu sense of, oh, that's what happened with SVB. And they went under and therefore the stock plummeted more than 40 percent on those headlines when that deal was actually solidified. They saw that it was a billion dollars led by Mnuchin's firm and some other heavyweight investors. The stock rebounded and people felt more comfortable.

6:45And it's that history that almost makes you wonder if I think you're referring to this, Karen, when did they really know about this two point four billion impairment? Was Mnuchin already looking over the books? Did he say, hey, I can get involved here, but you've got some work to do before we do that? And obviously they were in a really difficult place. The thing that's also just interesting to read headlines when you hear announcements from the new team and the investors saying, we actually now feel that New York Community Bank has enough reserves to deal with provisions and parts of the existing portfolio.

7:16I don't know how you do that. I mean, in other words, I think there's some dynamics out there. We talked about the idiosyncratic dynamic of New York Community Bank and why, in some sense, this isn't the whole sector, but that they have significant issues in terms of buildings that they own in New York or they've lent against, excuse me, that have significant rent controls around them. There's a lot of different dynamics with their loan portfolio that I'm not so sure right now, given the concerns that are happening, that you can say, hey, we think we're not only good here, but we're good to be able to deal with additional capital reserves.

7:46Fascinating that the KRE closes flat on the day. And if anything, over the last couple of days is in an upswing. And so that's telling you that the market is saying this is NYCB specific. Also, Fed Powell today made a reference to commercial real estate, and he said, we kind of think it's manageable. That was a great day to say it if you're NYCB trying to get this deal done. Yeah. You know, it's interesting, though, that the problem was they became too big and all of a sudden we're under the regulatory crosshair. So I wonder if this rattles investors' faith in small caps, because, you know, when you think about it, it was doing just fine until it reached a threshold of market cap and, you know, assets that triggered more regulation.

8:30So I just find this all so interesting. But are you saying they were doing just fine or no one knew how not fine they were doing? I suppose you could say it either way. But it makes you wonder, you know, OK, what about the rest of the regionals or the smaller banks? Right. Who was looking at the loan portfolio? I mean, it's not like it was an unknown that they had a large percentage of loans that were tied to rent controlled property. The regulator forced that deal. It was when the law was passed. We knew that rates were rising for a very long time. The most well telegraphed rate hiking cycle in the history of man.

9:04Is that in the model? Would you expect that? There's obviously it wasn't. Right. So we keep expecting these things to all be in the model. So now we flagged another one. That'll be put in to the next model. But the question is, who else hasn't put that in the model? What else hasn't been accounted for? Well, once that happens, the market will trade off of it. My understanding is that there was almost this kind of regulatory awakening when they crossed that$100 billion threshold. Suddenly, they were feeling pressure from the OCC, which hadn't historically regulated them as closely. And so the way that they were treating these loans, I think they expected more of a phase-in period after they acquired the signature assets, that they could kind of phase in some of these criticized loans, that it was more of a, you know, okay, well, we did this deal for you guys, so give us a grace period to work this through our books.

9:53And then the OCC came in there and was like, no, no, you have to criticize these now. These need to be reflective of a$100 billion bank. There is no phase-in period. You are over this threshold. you need to be acting like it. And so I think that was where the big surprise came in in the fourth quarter. They had to take more reserves as a result, slash the dividend. And so it was kind of this almost like a misunderstanding with their regulators on to what they expected following these large acquisitions. Which also does not instill confidence. Right. Right. Exactly. Which kind of feeds into the whole narrative here.

10:28Leslie, thank you so much. Leslie Picker, keeping us abreast of all the developments here. For more on what New York Community Bank Corp's lifeline means for the battered stock, let's bring in Chris McGrady, head of bank research at KBW, a Stiefel company. Chris has a market perform rating on the stock and outperformed not too, too long ago. And Chris, I want to just start off with where where we left it. You know, if New York Community Bank Corp had never acquired the assets of a signature, would we have known about, you know, the problems within their loan portfolio? Sure. Thanks, Melissa. So the problems in the loan portfolio really come down to concentration, right?

11:05New York community has been a concentrated business model in New York City, in multifamily apartment buildings forever. That's not new. The signature deal and the Flagstar deal a year ago actually made them less concentrated, still concentrated, but less so. Really, the issue is they crossed the hundred billion dollar level. and the OCC, while their prior previously were the regulator, we believe the scrutiny got turned up after the deal. And certainly this phase in period did not happen. So was that your when when the bank announced that it was acquiring those assets, did you think that there was a phase in period?

11:42I'm wondering how there is a misunderstanding about that when when you're buying assets and it's a deal that's blessed by the FDIC. We all did. Yeah, we actually upgraded the stock to outperform that night. We thought at$6, given the stock and given the capital relief, this was a great deal. We thought while the company had earnings challenges they were working through, diversification was moving in the right direction. So the phase-in period didn't happen. And certainly we didn't see this. We stepped away from the stock in December, but we certainly didn't see the speed of which this happened transpiring.

12:16So Chris, it's Karen. Thanks for being on today. So you have a buy on the stock. What is it? How do you model this? What are you hoping they achieve? What are you basing? What kind of metrics are you looking for here? No, just to be clear, we were birated last year. We stepped away in December. So we're market weight, the stock. Really, what we're going through, Karen, is we're trying to figure out with all the dilution that happened today. What is the normalized return on equity for the company? The stock closed at roughly 50 % of pro forma tangible book. And that would suggest the market's thinking an ROE in the 5 % to 6 % range is about right.

12:52We're hearing and we're talking to investors a lot about this reminds us of Citigroup from 2008 and the dilution. So the earnings power has certainly been diminished. There is earnings in this company. It's going to take time to come out. And I think today was the capital raise. But going forward, they're not done. They're going to sell assets. They're going to consider securitizations. Those were ideally going to be the first moves the company was going to make after earnings. The market forced their hand to do the equity race first. But clearly, we're trying to estimate what the earnings power.

13:22And it's probably a five to six, are we? Hey, Chris, it's Tim. So who's next? Because you can't tell me that idiosyncratic. I know the New York rent control market's difficult. We can all paint that picture. But it was a year ago that was SVB. It was held in maturity securities and a quick flight of capital that made that a problem. There's some issues out there. And it just seems to me that there are a lot of people that may be over their skis. Right. Commercial real estate's a big asset class, right? It's 40 percent roughly of a small bank's balance sheet. So the smaller banks, Tim, have more CRE.

13:56So that's where we're spending the focus. And they have lower reserves. So the incremental earnings pressure is going to be felt for the small banks. But if you step back, today was a big step in the right direction for the industry. Confidence has been really, really low. I think investors had feared this was going to be a zero for shareholders. And clearly, right now, that's not the case. So we are still thinking about what the normalized impact from credit is. But we don't think there's going to be a systemic concern from here. We've had a year. We're almost at a one-year anniversary of SVB.

14:25The industry's liquidity and deposit levels look very, very strong. There are earnings pressures, but systemic, we don't buy into that. All right. Chris, got to let you go. Thank you so much. Great. Thank you. Chris McGrady of KBW, what do you see on this? So when you look back on the issues that we had last year and when things were called a bailout, usually when you have a bailout, you buy the stock and the stock rallies. We didn't see that last year. We saw floods of money coming into money center banks to a J.P. Morgan, because they were the one that was solving the problem. Now you have another bailout.

15:03So for me, there's plenty of others that are going to be out there. The market's a pretty efficient place. They'll sell the ones that have the same issues. But if you're looking to buy the equity, where do you think it's going to go? The last spring taught us that the equity didn't go anywhere. Look back on some of these names that were troubled back then. The equity didn't go anywhere. Look back on some of the other names. They never got as high as they were before they sold off. So all this tells me is buy J.P. Morgan. I mean, I think that I kind of agree on the large over small argument. I mean, I think this just bolsters the idea that at least you know exactly what the large banks are doing.

15:45They know what the regulatory landscape looks like. They're, you know, potentially lower earnings risk than they have been historically lower leverage. But I don't know. I think about, you know, real estate back in 2009 and it felt similar. It was the idea that, you know, these companies needed to raise equity. And when they did, they sort of got a lifeline and they bounced a little bit. But then they just kind of remained dead money for a very long period of time. And I wonder if that's the path for for regionals. I mean, I think that what's interesting is you need a lender for the economy. and the only area of the economy that hasn't been allowed to lend are the big regulated banks.

16:25So I think this is an environment where, you know, you could potentially see that shift. Right. Did you actually put on the trade that we talked about this afternoon? I did. You did. And then I almost took it off, but I didn't, which was, Melissa and I were talking this afternoon about this before the Mnuchin thing, and I'm like, ooh, this looks really bad. I'm going to short some KRE. And then you text me the Mnuchin thing. I'm like, I'm going to look to cover. And then I'm like, you know what? I'm not going to look to cover because this isn't great. Right. And I thought, oh, should I do a KRE XLF kind of trade?

16:57I'm in your camp. I think to the beneficiary of this kind of disruption is the big money center banks. Right. Right. And also we got word from Powell today that they're reexamining the capital plans. Yeah. Big boost for the big banks. There's no question. And we thought one year ago that the big banks were had their hands tied once again. And I think it was at a time when actually the banks were starting to have a lot more freedom on their capital. I guess I agree with that. I mean, I look at what everybody's saying here. First of all, if you look at the BKX, so the large cap bank, essentially, you know, you double bottomed at 70 on the charts.

17:30You're up 40 percent off of that market inflection and you're now actually breaking out. And you're breaking out at a time when we are seeing some of the broader dynamics. It's great to have Savita back because I think she even talked about some of the old economy stocks that were going to benefit from the efficiencies of AI. And you're seeing this where people are willing to. It's easy to poo poo that the EPS growth has been disappointing, but the margin dynamics have been pretty impressive. All right. Meantime, Fed Chair Jerome Powell also saying in his testimony today that he is confident inflation will continue to move lower, but that more data is needed before the Fed can start cutting rates.

18:04Long-term Treasury yields were lower on the day, with the 10-year touching its lowest since February 7th. Let's bring in Paul McCulley, an adjunct professor at Georgetown's McDonough School and former PIMCO chief economist. Paul, always great to see you. Good to see you. Did we learn anything new from Powell in terms of the trajectory of rate cuts and or the landing point, the end point? No, I don't think we learned anything new today. We did get confidence that we heard right back at the last presser and also in his 60 Minutes interview that the tightening cycle's over. He did a valedictory on that.

18:42An easing cycle is going to come. He's warm and fuzzy about that. But he's not urgent about starting the easing process. And I think there are a couple reasons. One, the economy is still quite resilient, if not strong. And I think he agrees with that. And we also have the financial markets quite exuberant. So both of those factors say later, not sooner. But it's a done deal that we're going to get an easing cycle. And June seems to be a date that works for the market, works for me. I think it'll work for the Fed. Hoya Saxa, Professor McCauley from Hoya. I think you have an argument that the Fed's overly restrictive, but it's OK.

19:32How about the offset of the financial conditions out there being remarkably easy? Is that making it an OK environment for the Fed to hang in there longer? And I realize we don't know what the tail is and what the dog is. But if equities were doing something different, would you be more worried about the economy than you are today? I'm not sure if I'd be more worried about the economy because I think the equity market really is betting on the easing game. And it does ease financial conditions along with the other components of financial conditions. And that supports the economy. And on one side, that gives the Fed time because the financial markets are already stimulating or supporting the economy.

20:17On the flip side, it requires the Fed to ease in the fullness of time to validate what the market has done. Or if you want to put it very simply, ultimately, the Fed's got to re-slope the yield curve. An inverted yield curve with easier financial conditions is not a completed project. You ultimately have to have a re-slope yield curve. The Fed has to validate it. And assuming that they do, then we will have the soft landing scenario. Paul, what's going to be the tell? For me, it's they can't do QT and be cutting rates at the same time. There's too much push-pull there. So once we see them end QT, that gives me the sign that the next go-around is the cut.

21:09Do you agree or why don't you agree? I actually disagree with that. I think that QT and the policy rate are separate variables. They're separate tools. And I don't think there's any impediment whatsoever to the Fed starting the easing process and continuing QE to QT. And I think QT is going to be tapered maybe even in March, but certainly this spring, so as that they're not at the pace that they've been for the last 18 months. Paul, thanks for joining us. Always great to see you. Paul McCulley, AgDunner Professor at Georgetown now. So, Savita, what'd you make of today's test? Does it change anything?

21:55You're already getting more bullish on the markets. I am, yeah. I mean, I feel pretty good about markets. I think, you know, we've written a lot about how the bear cases that we hear don't necessarily hold water. So, you know, the idea that the market's too expensive. Well, if you compare the S &P today to the S &P in 1980, yeah, it looks more expensive, but it's a completely different animal. It's got, you know, 50 % of it is asset light versus 30 years ago, it was more manufacturing. I think, though, what's interesting, just from listening to the professor, is the idea that we're not going to see another Fed hike.

22:35So I think that could be the bearish scenario. But there is one. I mean, just, you know, inflation, is it under control? Maybe it comes back a little bit. And if we did see another Fed rate hike, I don't think that would be so terrible. What's another 25 basis points? There's, you know, cash rich investors would make more money on their cash. Tech companies are net cash positive. It would probably be OK from a fundamental perspective. But I just wonder if that's completely off the table. I wonder if it's off the table, both a cut and a raise, just because of the political environment. Right, exactly.

23:10Whether or not the data supports one of those doesn't matter. We kind of hope it, right, as a citizen. I mean, we have this independent central bank that we don't want to be. So they may not do what they need to do just to show they're independent. But no, we've got three cuts. We've got three cuts baked in. I agree. Yeah. Coming up, a check on China Tech. Shares of JD.com surging after earnings in the broader Chinese internet space is jumping along with it. How to trade these names next. And we are stepping back on the scale to hit the weight loss drug race. How rising costs could impact those in need and how the government could step in.

23:43More on that when Fast Money returns. This is Fast Money with Melissa Lee. Right here on CNBC.

23:59Welcome back to Fast Money. JD.com topping the tape today, having its best day in almost two years. The Chinese e-commerce company surging more than 16 percent after posting a beat in the top and the bottom lines. Revenues in the latest quarter rose 3.6 percent from a year ago. The company also announcing a three billion dollar share buyback. There's so many concerns about the competitive threats, which they did seem to acknowledge in some respects, but specifically from PDD, which is the owner of Timu, Shop Like a Billionaire. It's very competitive. And so if you think about that environment, the question is if you're investing in Chinese e-commerce names and even Internet companies more broadly based upon fundamentals or not.

Read the full transcript

24:37Because, again, on fundamentals, if you look at the cash and the balance sheets of J.D. and they talked about this buyback, I think Alibaba has somewhere in the nature of 80 billion in cash or equivalents with 180 billion dollar market cap. So, I mean, everything about these companies says buy, buy, buy. And I think the fundamentals are starting to look better based on this profit dynamic that people can allow them to focus on the names themselves. These are great numbers. These are great numbers. And I think they're coiled springs. I just don't think people are jumping on the other side of that seesaw yet.

25:09I mean, I've definitely added to Chinese Internet names over the last couple of weeks. And I feel like I can own them for the long term and doing that for clients as well. I mean, the politics around it in terms of what the Chinese government might do. And then also on the dynamic of an election year, there'll be a lot of rhetoric about tariffs and, you know, U.S.-China relations getting worse. It's the one thing that D.C. agrees on. It's a bipartisan issue. Everyone has China in the crosshairs. But if you look at the market, to Tim's point, the market has lost$6 trillion worth of wealth in that market.

25:41So can you if you look at any chart, the charts all unanimously look terrible. Can they bounce from a much lower cost basis? Of course they can. Am I willing to take that risk? I don't think I'm there yet. All right. There's a lot more fast money to come. Here's what's coming up next. Slimming down your waist and your wallet. Will the rising cost of weight loss drugs impact those most in need? The details on that one ahead. Plus, lifting up. A five-star ride for the stock in today's session. and one of our traders is staying long on this ride, the rideshare tear, next. You're watching Fast Money, live from the NASDAQ market side in Times Square.

26:23We're back right after this.

26:30Welcome back to Fast Money Stocks. Bouncing back from yesterday's sell-off as investors digested testimony from Fed Chair Jerome Powell. The Dow climbing 75 points. The S &P and NASDAQ both jumped half a percent. Shares of Brown-Formin sinking 7 % after the Spirits maker lowered its annual organic net sales forecast. Brown-Formin the worst performer in the S &P today and turning negative for the year with today's drop. Dexcom meantime surging nearly 10 % after the FDA cleared the company's first ever over-the-counter glucose monitor patch, which will be available this summer. The patch is designed for patients with type 2 diabetes who do not use insulin, and it is the first glucose biosensor that does not require a prescription.

27:08And NVIDIA, this is worth noting, higher yet again today, up 3%, now up nearly 8 % just this week. And it's only Wednesday. And gold also glistening today, hitting an intraday all-time high, settling on a new record. And Bitcoin also bouncing back after its big drop yesterday. The crypto touching a new record level of$69 ,000 before making a sharp downturn to climb back to around$67 ,000 today. Coming up, a five-star move for one rideshare stock. Stock lift surging on the back of some big upgrades this week, and the move has one of our traders adding to his position why he is flexing his blyceps next.

27:46But first, heavy costs in the weight loss drug space, the consumers being impacted, and what exactly can be done as the obesity drug battle rages on? The details when Fast Money returns. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

28:10Welcome back to Fast Money. The debate around GLP-1 drug prices and availability rages on with concerns that ballooning costs could limit access and cost the government billions. Monday, former NEC Director Brian Deese wrote in a New York Times op-ed saying the U.S. government should try to lower prices through its Medicare purchasing program, but not all experts agree that that's the most effective way to control costs and blunt the impact on the federal budget. Former FDA commissioner and CNBC contributor Dr. Scott Gottlieb joins us now. Scott, great to see you. And we had a very heated discussion surrounding this yesterday.

28:43And we also had some question marks around some of the numbers, the eye-popping numbers that Deese had outlined in the op-ed. And you also took issue with some of those numbers. What, in your opinion, did Deese miss? Well, there's no question this is going to cost Medicare a lot of money, but not nearly what was estimated in that op-ed. First of all, they wrongly used list price to make their assumptions on what the cost would be rather than the net price. We know discounting is very heavy in the market right now on the order of 40 to 60 percent between Wagovi and Zepan. It's only going to get more intense.

29:16And also they wrongly assumed, it appears, that this was approved under a biologics license application. That's a biological. And in fact, it was approved under a new drug application. And therefore, it's already subject to the price negotiation within the IRA, within Medicare. And it's probably going to go on the list this year. So it's probably going to be subject to the negotiated price as early as 2027. And some analysts on Wall Street are also estimating that. And so the notion of the op-ed was that we need to extend the price negotiation under the IRA to encompass these drugs, because otherwise they won't be subject to the negotiated price until 2030, they said in the op-ed.

29:50And in fact, they'll be subject to the negotiated price as early as 2027. And they'll go on the list probably. Semaglutide will probably go on the list this year based on when it when it was approved. It was approved in December of 2017. That's seven years out. And so therefore, it's subject to negotiation. Novo is probably regretting that they got it approved in December of 2017 rather than January 2018, because now it's seven years. Right, right, right. Right. He should have, Dee should have talked to some of the analysts on Wall Street who are already factoring in 27 being the year in which it would go on the Medicare list in terms of up for negotiation.

30:23I'm wondering, though, because, you know, you mentioned Ozempic specifically when Govi was approved later on for weight loss specifically. And so is there a difference in terms of what is able to be negotiated in terms of what the use of the molecule is? So the price negotiation, the negotiated rate is going to be applied to semaglutase. So it's going to encompass all the formulations. And so presumably, based on how Medicare has behaved in other settings similar to this, they're going to extend that not just to the formulation for diabetes, Ozempic, but also the formulation for weight loss, Wagovi.

30:56So that, too, will be subject to the negotiated price as early as 2027. How do you think about the gains, though, to society that that decent really factor in that a lot of other people are thinking more broadly about? I mean, theoretically, if you're not having a serious cardiovascular event, you're not missing work, for instance, or if you're if you're not in need of knee surgery because you're not obese, you're not missing work either. Yeah, it's not just the productivity benefits that we're going to see from this, but also the direct health benefits. And they could be quite substantial. There's a lot of comorbidity inside the Medicare population related to weight.

31:31And it also underscores the fact that a lot of people are going to be newly eligible for these drugs even before Medicare expands coverage for weight loss. And so their assumption in the op-ed was that once Medicare expands coverage for weight loss, then all these patients will be newly eligible for the drug. And in fact, as new indications get on the labels of these drugs, and Gobi's probably going to get an indication for cardiovascular risk reduction this year, those patients will become eligible for the drug. because even though Medicare doesn't cover drugs for weight loss, they do cover drugs for cardiovascular risk reduction.

32:01If you look at the numbers right now, there's about 23 million Medicare beneficiaries that have had a prior stroke or MI. If you figure half of them are already eligible for this drug because they have diabetes, and then half of the remaining patients probably qualify based on BMI, that gets you to around 5 to 6 million patients who will be newly eligible under Medicare for Wagovi once it gets that label expansion probably this year. And the total population of Medicare patients who would be eligible just based on BMI alone is probably roughly around 20 million. So 25 percent of that population will be eligible just based on the label expansion this year.

32:34And it's only going to increase as they get indications for sleep apnea, chronic kidney disease and other comorbidities. Hey, Scott, it's Tim. Thanks. And thanks for putting numbers to that, because the DS op ed. You know, some people just think a lot of this is politics. your views on the political season and the two now parties going toe to toe. Give your thoughts on drug pricing proposals from each side. I think what you what you believe might surprise some people. Well, I do think that this op ed was probably a walk up to the State of the Union, where the president's likely to announce a dramatic or a proposed dramatic expansion of the Inflation Reduction Act and the negotiated prices to a broader segment of drugs.

33:14And they've already put that in the budget. So I think a lot of that's been previewed. I think the scuttlebutt inside the community, the pharmaceutical community, if you will, is that the proposals put forward by former President Trump actually could have a more dramatic impact on the industry than the proposals being put forward by President Biden in terms of expansion of the IRA. First of all, I think most people don't expect the expansion of the IRA to actually be enacted. I think the presumption is that the Republicans probably get control of the Senate, regardless of what happens with the House and the presidency.

33:45But if President Trump were to win, even if there was a Democratic Senate, and it's unlikely that there would be a Democratic Senate, what he's proposing is to index prices in Medicare to European drug prices. And if they don't adjust that for GDP per capita and they apply it retrospectively, so they apply it to already marketed drugs rather than prospectively just to drugs that are newly launched, that could have a dramatic one time effect on the pharmaceutical industry's revenue. And when they proposed that in the past as a regulation, they did apply it retrospectively. So to already marketed drugs now would have a very dramatic effect.

34:17And I think, quite frankly, it's probably more likely to pass because Republicans would support it because they'd want to support the president. And Democrats would support it because they want to take money away from the drug industry. Dr. Gottlieb, thanks for being on. Do you think that we could see this not being a duopoly in, I don't know, two years or so, and that that would also decrease the pressure on pricing? Well, certainly. And also, these companies have follow on molecules in development. They're probably more than, you know, a couple of years away. They're going to have pivotal data probably next year.

34:50And so you probably wouldn't see approval until maybe 2026. But I think there's also going to be competition from oral formulations of drugs where patients could get cycled off of some of these injectables once they achieve some initial weight reduction and get maintained on some of the oral drugs, including the oral drugs that are currently in the market. I think doctors are going to find different ways to manage these patients so they're not necessarily on these injectables in perpetuity. But as as these labels expand, you're going to see pretty intense, I believe, price competition between Lilly and Novo here.

35:18This isn't just a battle of which is the best drug, but which drug has the best label. And for a time, Novo is probably going to have the better label because they're going to get that select trial data into their label, the evidence for cardiovascular risk reduction. So in order to compete, Lilly's probably going to have to discount more because Novo is going to have the better label for perhaps a year until Lilly turns over the card on the trials they have in CHF and sleep apnea and maybe get approvals for those indications sometime in 2025. Scott, always great to see you. Thank you. Thanks a lot.

35:53Dr. Scott Gottlieb. Were you long, Lilly? No. So, no, I was long Amgen and I'm out of Amgen. It was part of my wage, and I'm actually only long still two of those letters in that acronym. So when you look at a NOVA or you look at a Lilly, it definitely is a two-party race at this point. And you see how difficult Amgen had a time of doing it. And they lost. So I think it's still theirs. Yeah. Are you starting to think about the impact on productivity and even the economy in terms of your stock market forecast? In terms of just the GLP ones. I mean, that's a great point. I think it's obviously it's going to change a lot of factors like the need for prosthetics.

36:37And, you know, just I think the array of possibilities is wide. What I find really fascinating, though, is we've seen this movie before. Every presidential election year where we start the year with a big overweight in health care. And let me tell you, when you look at the holdings of mutual funds, hedge funds, everyone, pharma, like these stocks are the core holdings of your average fund manager. This is I just feel like this is such a setup for health care where it's, you know, you always you get this tweet, you get Medicare for all, you get, you know, something happens during campaign season.

37:10So this makes me think that we're not necessarily positioning for the election yet. All right. Coming up, why Tim is going all in on the L in Blysep. The ride share stock lifting his spirits this year. He'll lay out what he thinks is prime for even more gains ahead. Pretty happy right there. And meantime, Foot Locker shares falling off a cliff today, down nearly 30 percent. The major headline that has investors scrambling for a foothold right after this.

37:39Welcome back to Fast Money. Shares of Lyft jumping 8.5 percent today, now up nearly 17 percent in the past week. But even with these gains, it's not quite back at its recent post earnings high. Lyft, of course, is part of Tim's newly modified acronym. It just rolls off the tip of your tongue. Which is not a real word, obviously. He's adding to his position today. So why? It's amazing the flexibility we're given in the acronym game. And I need it, by the way, because I think I'll take anything I can get. I'm a little behind here. My view is on Lyft. There's a couple big picture dynamics with both transportation as a service and mobility.

38:12And you talked about a duopoly essentially in GLP land. Well, I mean, Uber and Lyft, there's a significant difference in where they trade. And there's probably a reason for that. But the profitability and the numbers that they showed for those 4Q numbers, the fact that they're executing on cost savings and efficiency, the fact that some of the tailwinds from additional drivers, so they've got 25 percent more drivers, they have 47 percent more supply of driver available hours. These were things that were killing this company during the kind of the post-COVID normalization process. I just think some of this is a combination of there's a 12 percent short interest in the stock.

38:48The company's had a couple of good quarters of numbers. The street has absolutely proved me on this. Every analyst says these are good numbers. I want to see another quarter or two of this. But to me, this is a case where this is a$30 stock before it's a$14 stock, I think. And I think it's a combination of valuation discount to Uber that they've gotten their act right. But the tailwinds for the industry are great. And there's only two players. So I like Lyft, and I've been adding to a position over the last three or four months. Where are you on 30 over 14? It sounded great when it rolled off his mouth.

39:20I was agreeing. It's confident. Yeah, it was extremely confident. When you look at the chart, it's a terrible chart longer term. But when you look at the performance against Uber, it's been outperforming, or very close to Uber on a longer term. I like Uber because you're looking at a huge mammoth company, and Lyft is a very small company in relation in the relationship to Uber. Uber's got a lot more levers to pull. So when they don't perform here, they could perform some for something else. They'll get the benefit of the doubt. But coming from such a low price and being beaten up for so long, I could see where he's excited about the stock.

39:57Right. Coming up to left feet for Foot Locker as a sneaker retailer plummets after its latest earnings. How long the company now expects before turning a profit and how investors are untying from this one. That is next. More Fast Money in two.

40:15Welcome back to Fast Money. Foot Locker getting kicked in the teeth. Shares plummeting nearly 30 percent after the retailer reported a holiday quarter loss. A sneaker retailer also issuing weak guidance saying the profitability goal laid out last March will now be delayed by two years. The company has been in the midst of a turnaround under former Ulta boss Mary Dillon. Shares had been up 10 percent on the year before today's loss. Karen, you were a big fan, were maybe a big fan of Eric D. Well, it was in my last year's trade, which if I still had, it would make this year's trade phlegm. I'm happy that that's not the case for a couple more reasons.

40:46I do still have a small position, actually a fairly smaller position today after this. But I think that it's a little misleading. This was their plan for 26. They've moved it out to 28. So it's not like this was supposed to be the plan for 24. But anyone who's been following this story, like I have for the last year, knows that that 26 was not happening. Right. They still had too much inventory. She was still in the middle of a and still is in the middle of a big change out of malls into more superstores, a big capital expenditure. She's trying to do a lot of different things and digital. So she put out a new earnings between, I don't know, around a buck 50 in the midpoint.

41:25So the stock here at 15 and a half times for a turnaround that still hasn't shown legs to the extent that it should have is not overly compelling here. What percent are Nike sales of their total revenue at this point? Sixties? No, no, no. Lower than that. And it has been lower. That's not a new part of the story. And there's a lot of strength elsewhere. I mean, Onn and Hoka and New Balance. How long do you stick with this trade? I feel like I'm kind of, I don't have a big position now. Now, I keep these things around just to make me feel bad when they go down and not feel good when they go up.

42:07It's working. Right. Mission accomplished. So, no, it's a small bet. I'll feel bad if it gets taken out tomorrow. Can you spell phlegm? No, not in the real way. It's a great spelling bee word. It really is. That would be a very good acronym. Karen's very smart. We're playing a xylophone. We got to go. Final trade's up next.

42:31Time for the final trade. Savita. I like XLE. Energy, I think it's, we're entering driving season. Everybody hates energy. It didn't work at all. Love that. Love that. Great to have you here tonight, Savita. Tim? Great having Savita, and great having Savita say she's not going to go on any other shows on CNBC but Fast Money, which is great. Silver has been underperforming gold SLV. Karen? Yes. I still like EWW for on-shoring and near-shoring into Mexico. Grasso. JetBlue back to that level where we saw that Carl Icahn headline. All right. Thanks for watching. Fast. See you back here tomorrow at 5.

43:05Mad Money with Jim Cramer starts right now.

43:11All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, Internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:45To view the full Fast Money disclaimer, please visit CNBC.com forward slash Fast Money disclaimer.

From the publisher

New York Community Bank raising more than $1B in equity led by Fmr US Treasury Secretary Steve Mnuchin… but is it enough to save the beaten down bank? Plus… slimming down your waist, and your wallet. A deep dive into weight-loss drug costs, and how it’s impacting those who need it the most.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
New York Community Bank Gets A Lifeline… And Heavy Costs For Weight-Loss Drugs 3/6/24CNBC's "Fast Money" · 44 min
Listen in VO